Disease

• These innovations underscore the progress in agriculture sensing technologies, enabling farmers to manage resources efficiently and sustainably, fueling the expansion of the global agriculture sensing and monitoring devices market.
• (Exact word count: 50)
  Agriculture sensing and monitoring devices are transforming modern farming practices.
• The global agriculture sensing and monitoring devices market faces a significant challenge due to the high initial costs associated with adopting these technologies.
• Overall, agriculture sensing and monitoring devices are crucial for optimum production, productivity, and crop yield in the face of food demand, arable land, and various environmental pressures.

• This prestigious event will bring together more than 500 influential leaders from New York City's real estate and construction industries for an evening of networking, celebration, and raising crucial funds and awareness to support those impacted by Alzheimer's disease and related dementias.
• Since its inception, the event has raised over $1.5 million to support groundbreaking research, caregiving services, and advocacy efforts.
• In honor of World Alzheimer's Day on September 21, CaringKind is partnering with prominent New York City landmarks to light the skyline in purple.
• On the evening of September 18, the following buildings will illuminate in purple to show solidarity with those affected by Alzheimer's and related dementias:

• Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2 positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting.
• An additional endpoint analysis of CNS ORR in patients with brain metastases at baseline showed ENHERTU demonstrated a CNS ORR of 62.3% (95% CI: 50.1-74.5; n=38/61) in patients with active brain metastases and 79.2% (95% CI: 70.2-88.3; n=61/77) in patients with stable brain metastases.
• A post-hoc analysis in patients with active brain metastases showed the CNS ORR was 82.6% (95% CI: 67.1-98.1; n=19/23) in untreated patients and 50.0% (95% CI: 34.1-65.9; n=19/38) in patients with treated/progressing brain metastases.
• The most common grade 3 or higher adverse events occurring in 5% or more of patients in either cohort included neutropenia (16% in brain metastases and 18% in non-brain metastases), fatigue (9% in brain metastases and 10% in non-brain metastases), anemia (7% in brain metastases and 5% in non-brain metastases) and nausea (5% in brain metastases and 5% in non-brain metastases).

• Many voters are willing to accept misinformation from political leaders – even when they know it’s factually inaccurate.
• According to our research, voters often recognize when their parties’ claims are not based on objective evidence.
• Yet they still respond positively, if they believe these inaccurate statements evoke a deeper, more important “truth.” Our team conducted a series of online surveys from 2018 to 2023 with over 3,900 American voters.
• These surveys were designed to elicit responses about how they evaluated political statements from several politicians, even when they recognized those statements as factually inaccurate.

Why it matters

• However, our discovery illustrates the deeper but overlooked drivers behind voters’ tolerance and support for factually inaccurate statements.
• The findings suggest that misinformation survives not only due to voters’ “gullibility” but their moral calculations about whether partisan ends justify the means.

What still isn’t known

• Our research leaves critical questions about how to combat such moral flexibility and its consequences.
• To be sure, we do not see such moral flexibility as categorically wrong.

What’s next